Indeed, therapeutic concepts have been proposed, for example, for KRAS mutant pancreatic cancer, in which the combined inhibition of mTORC1/2 and MEK precludes adaptive resistance [51]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.